Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies.
Körper S, Jahrsdörfer B, Corman VM, Pilch J, Wuchter P, Blasczyk R, Müller R, Tonn T, Bakchoul T, Schäfer R, Juhl D, Schwarz T, Gödecke N, Burkhardt T, Schmidt M, Appl T, Eichler H, Klüter H, Drosten C, Seifried E, Schrezenmeier H. Körper S, et al. Among authors: seifried e. Transfus Med Hemother. 2021 May;48(3):137-147. doi: 10.1159/000515610. Epub 2021 Apr 21. Transfus Med Hemother. 2021. PMID: 34177417 Free PMC article.
Validation of Virus NAT for HIV, HCV, HBV and HAV Using Post-Mortal Blood Samples.
Gubbe K, Scharnagl Y, Grosch S, Tonn T, Schmidt M, Hourfar KM, Karl A, Seifried E, Wilkemeyer I, Kalus U. Gubbe K, et al. Among authors: seifried e. Transfus Med Hemother. 2012 Dec;39(6):381-5. doi: 10.1159/000345319. Epub 2012 Nov 13. Transfus Med Hemother. 2012. PMID: 23801525 Free PMC article.
Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19-Convalescent Donors.
Jahrsdörfer B, Groß R, Seidel A, Wettstein L, Ludwig C, Schwarz T, Körper S, Rojewski M, Lotfi R, Weinstock C, Seifried E, Corman VM, Drosten C, Münch J, Schrezenmeier H. Jahrsdörfer B, et al. Among authors: seifried e. J Immunol. 2021 Jun 1;206(11):2614-2622. doi: 10.4049/jimmunol.2100036. Epub 2021 May 12. J Immunol. 2021. PMID: 33980583
Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19.
Körper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman VM, Grüner B, Ernst L, Spieth P, Lepper PM, Bentz M, Zinn S, Paul G, Kalbhenn J, Dollinger MM, Rosenberger P, Kirschning T, Thiele T, Appl T, Mayer B, Schmidt M, Drosten C, Wulf H, Kruse JM, Jungwirth B, Seifried E, Schrezenmeier H; CAPSID Clinical Trial Group. Körper S, et al. Among authors: seifried e. J Clin Invest. 2021 Oct 15;131(20):e152264. doi: 10.1172/JCI152264. J Clin Invest. 2021. PMID: 34464358 Free PMC article. Clinical Trial.
Human immunodeficiency virus 1 dual-target nucleic acid technology improves blood safety: 5 years of experience of the German Red Cross blood donor service Baden-Württemberg-Hessen.
Hourfar K, Eberle J, Müller M, Micha Nübling C, Chudy M, Kress J, Gürtler L, Mayr-Wohlfart U, Schrezenmeier H, Hellmann I, Luhm J, Kraas S, Ringwald J, Gubbe K, Frank K, Karl A, Tonn T, Jaeger M, Sireis W, Seifried E, Schmidt M. Hourfar K, et al. Among authors: seifried e. Transfusion. 2018 Dec;58(12):2886-2893. doi: 10.1111/trf.14919. Epub 2018 Oct 16. Transfusion. 2018. PMID: 30325043
375 results